62.72MMarket Cap-1.03P/E (TTM)
2.090High1.934Low680.04KVolume2.000Open1.960Pre Close1.37MTurnover3.04%Turnover RatioLossP/E (Static)31.05MShares7.68052wk High1.09P/B45.23MFloat Cap1.00052wk Low--Dividend TTM22.39MShs Float33.990Historical High--Div YieldTTM7.95%Amplitude1.000Historical Low2.013Avg Price1Lot Size
Immuneering Stock Forum
IMM-1-104
Further IMM-1-104 Phase 2a data expected in the second quarter of 2025
Initiation of Phase 2a arms of IMM-1-104 in combination with a BRAF inhibitor, as well as IMM-1-104 in combination with a checkpoint inhibitor, planned for 2025
Immuneering's Cancer Drug Shows 50% Response Rate in Phase 2a Pancreatic Cancer Trial, Beating Benchmark
On January 13, 2025, Immuneering Corporation (the "Company") announced updated interim response and safety data from the ongoing Phase 2a arm evaluating IMM-1-104 with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients, part of the Company's ongoing Phase 1/2a clinical trial of IMM-1-104 in patients with advanced RAS-mutant solid tumors.
The Company announced that, as of January 6, 2025, of the six evaluable patients in the ...
Anyone understands why the stock price keep dropping despite of the positive news?!!!
The rapid progression of IMM-1-104's development program is noteworthy. Having two parallel first-line pancreatic cancer combination arms showing comparable response rates strengthens the drug's potential positioning. The planned expansion into BRAF inhibitor and checkpoint inhibitor combinations in 2025 suggests a comprehensive development strategy targeting multiple therapeutic approaches.
The Q2 2025 data update will be crucial, as it wil...
Immuneering Provides Positive Update on Phase 2a Arm Studying Imm-1-104 in Combination With Modified Folfirinox for First-Line Pancreatic Cancer
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
Monday, 13th January at 8:00 am
- Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer -
- Overall Response Rate (ORR) of 50%; historic benchmark of 32% for FOLFIRINOX alone -
- Nearly $14M in net proceeds raised in January 20...
All analysts expecting the stock to raise to minimum $8 and the morningstar evaluation for the stock price is $6, but the stock keep falling dramatically even after the hot news!!
What’s going on? anyone have any idea? or any insights?
No comment yet